Balyasny Asset Management LLC Aldeyra Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $71,824 - $296,091	-48,860 Reduced 72.3%	18,720 $65,000
Q3 2023 Nov 14, 2023	BUY	$6.11 - $8.16 $322,149 - $430,236	52,725 Added 354.93%	67,580 $451,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $82,646 - $138,209	-11,624 Reduced 43.9%	14,855 $124,000
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $26,778 - $46,085	-4,641 Reduced 14.91%	26,479 $262,000
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $158,089 - $220,640	31,120 New	31,120 $216,000
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $124,904 - $177,665	-11,964 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $78,124 - $172,520	11,964 New	11,964 $142,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.